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Abstract
The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients with microbiologically
documented infections is currently unknown. We conducted a retrospective multicenter cohort study in 7 Portuguese
intensive care units (ICU). We included 569 critically ill adult patients with a documented infection and treated with
piperacillin/tazobactam admitted to one of the participating ICU between 2006 and 2010. We successfully matched 173
pairs of patients according to whether they received continuous or conventional intermittent dosing of piperacillin/
tazobactam, using a propensity score to adjust for confounding variables. The majority of patients received 16g/day of
piperacillin plus 2g/day of tazobactam. The 28-day mortality rate was 28.3% in both groups (p = 1.0). The ICU and in-hospital
mortality were also similar either in those receiving continuous infusion or intermittent dosing (23.7% vs. 20.2%, p = 0.512
and 41.6% vs. 40.5%, p = 0.913, respectively). In the subgroup of patients with a Simplified Acute Physiology Score (SAPS)
II.42, the 28-day mortality rate was lower in the continuous infusion group (31.4% vs. 35.2%) although not reaching
significance (p = 0.66). We concluded that the clinical efficacy of piperacillin/tazobactam in this heterogeneous group of
critically ill patients infected with susceptible bacteria was independent of its mode of administration, either continuous
infusion or intermittent dosing.
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Introduction
The primary determinant of piperacillin/tazobactam efficacy is
the amount of time in which the non-protein bound drug
concentration (fT) exceeds the minimum inhibitory concentration
(MIC) of the microorganism (fT.MIC) [1]. Piperacillin/tazobac-
tam was approved to be administered by intermittent dosing.
However with intermittent dosing, b-lactams attain a high peak
concentration, but the presence of increased clearance can lead to
a short half-life and a sub-optimal fT.MIC [2,3]. Furthermore,
optimizing fT.MIC is particularly difficult for microorganisms
with elevated MICs.
Pharmacokinetic studies have shown that prolonging the
infusion time provides more consistent serum levels and maximizes
fT.MIC [4,5]. It is unclear, however, if this approach could be
translated into better patient outcomes.
Several trials comparing clinical outcomes of extended or
continuous infusion of b-lactams with intermittent dosing have
been completed, with conflicting results [6,7,8]. Moreover the
interpretation of those studies remains controversial, as most trials
were single centre studies, conducted with a small number of
patients and failed to control for potentially confounding variables,
such as focus of infection or length of hospital stay before
inclusion. Besides, two recent meta-analyses failed to show any
clinical benefit of extended or continuous infusion of b-lactam
antibiotics in these unselected hospitalized patients [9,10] suggest-
ing the need to define sub-groups of patients who might benefit
from this strategy.
In clinical practice continuous or extended infusion of
piperacillin/tazobactam is often recommended [2,11]. Therefore
we intended to analyse if this approach may lead to a significant
clinical benefit in an unselected population of critically ill patients.
We performed a multicenter propensity matched analysis
comparing continuous infusion with intermittent dosing of
piperacillin/tazobactam in critically ill patients with microbiolog-
ically documented infections to determine if continuous infusion
resulted in improved 28-day survival, compared to conventional
intermittent dosing.
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Materials and Methods
Setting
This study was performed in 7 adult Intensive Care Units (ICU)
in Portugal.
All patients admitted to one of the participant ICUs between 1st
January 2006 and 31st December 2010 were eligible for analysis if
they received piperacillin/tazobactam during their ICU stay to
treat a microbiologically documented sepsis with one or more
microorganisms with in vitro susceptibility to piperacillin/tazobac-
tam. Microbiologically documented sepsis was considered when a
relevant microorganism from a suspected focus of infection was
isolated and/or bacteraemia was present. Further inclusion criteria
included receiving at least 24 hrs of the studied antibiotic in the
ICU.
Piperacillin/tazobactam was administered either by 30 min
intermittent dosing or by continuous infusion, after an initial bolus
of 4.5 g, according to the attending physician.
We excluded patients with infections caused by piperacillin/
tazobactam resistant microorganisms (according to in vitro testing),
with renal failure (defined as the need of renal replacement
therapy during their ICU stay), or with incomplete clinical data.
All patients were followed until death or hospital discharge.
Each patient could be included only once. Repeated admissions
were discarded from further analysis and only the first admission
was considered.
All data from this population were included in a database
created specifically to this study.
The Institutional Review Board and Ethics Committee of all
participating hospitals approved the research protocol and waived
the need for written informed consent due to the observational
nature of the study.
Design
We conducted a retrospective propensity matched cohort study
using prospectively collected data. We divided the patient
population according to whether they received piperacillin/
tazobactam by continuous infusion or conventional intermittent
dosing. For the purpose of the study we considered the form of
administration in the first 48 hrs.
The primary endpoint was the 28-day all cause mortality.
Secondary endpoints were ICU and hospital mortality and length
of stay.
Definitions
Demographic data was collected. Site of admission was
classified as emergency room, ward or another ICU. Primary
source of infection was divided in lung, intra-abdominal, genito-
urinary, skin and soft tissue, endovascular (including endocarditis
and central venous catheter infections), central nervous system and
others. The length of time in the ICU before the diagnosis of
infection was divided in 4 sub-groups: less than 72 hrs, 3–7 days;
8–28 days and more than 28 days. Microbiological isolates were
aggregated in Gram positive, non fermentative Gram negative or
other Gram negative bacteria.
Patients were classified according to the use of systemic steroids,
vasopressors and the need of mechanical ventilation.
Matching by Propensity Score
As this was a nonrandomized study, there was a possibility that
there were inherent differences between the two groups. To
overcome these limitations, we used a propensity score to match
patients according to the mode of piperacillin/tazobactam
administration. By using propensity scores, one can better control
for the likelihood of being assigned to a group and therefore
reduce occult bias [12]. In our study, we modelled the likelihood of
receiving continuous infusion therapy using logistic regression. We
included in our regression model gender, age, severity of illness at
ICU admission assessed by the Simplified Acute Physiology Score
(SAPS) II score [13], admission from emergency room, ward or
another ICU, the use of vasopressors, systemic steroids, invasive
mechanical ventilation, source of infection, microbiological isolate
and length of time in the ICU before starting piperacillin/
tazobactam.
This analysis allowed the calculation of the probability of
receiving piperacillin/tazobactam by continuous infusion for each
patient. The propensity score area under the receiver operating
characteristic curve was 0.74, indicating good discrimination
(Hosmer and Lemeshow goodness of fit test, p = 0.741).
Subsequently, patients who received piperacillin/tazobactam by
continuous infusion were matched with patients treated with
intermittent dosing with the nearest propensity score (within a
range of 0.01 on a scale from 0 to 1), using a neighbour matching
methodology. Matching was performed without knowledge of the
patients’ outcomes.
The success of this matching was assessed by evaluating
differences in individual demographic data (Table 1).
After matching was completed, this new data set constituted our
study population to assess the effect of piperacillin/tazobactam
mode of administration on outcomes.
Statistical Analysis
Descriptive statistical analysis was performed. Continuous
variables were expressed as median [interquartile range] or mean
6 standard deviation according to data distribution. Comparisons
between infusion groups were performed with paired Student’s t
test for continuous variables or McNemar’s test with continuity
correction for categorical variables, to account for the matched
design.
Cumulative mortality was calculated for continuous and
intermittent dosing groups during the first 28 days after receiving
the first dose of piperacillin/tazobactam.
Sub-group analyses were performed for patients with pneumo-
nia, for patients treated with monotherapy, for those receiving
vasopressors and according to the isolated microorganism
(Pseudomonas aeruginosa, Gram positive or other Gram negative
bacteria). In order to evaluate a potential mortality benefit of
continuous infusion in the sub-group of patients with the higher
severity scores, as described by Lodise et al [14], we performed a
similar analysis using the SAPS II score. Accordingly we stratified
the patients to identify the SAPS II cut-off, which allowed splitting
the data and select the sub-group with the largest 28-day mortality
difference between patients receiving either continuous infusion or
intermittent dosing of piperacillin/tazobactam. Chi-square test
was used to test association between type of infusion and mortality
in these sub-groups. The Mann-Whitney U test was used to test
association between the type of infusion and the length of stay in
patients who were discharged from the ICU and the Hospital.
Data were analyzed using PASW Statistics v.18.0 (SPSS,
Chicago, IL). All statistics were two-tailed, and significance level
was defined as p,0.05.
Results
During the study period a total of 569 patients admitted to one
of the participating ICUs received at least 24 hrs of piperacillin/
tazobactam to treat a microbiologically documented sepsis.
Piperacillin/Tazobactam Continuous Infusion
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According to the propensity score a total of 173 pairs (N= 346
patients, 61% of total population) were successfully matched and
enrolled in the study. Groups were well balanced as shown in
Table 1.
The main focus of infection was the lung, which constituted
70.8% of all infections. Gram-negative bacteria were predominant
(81.8%) in all studied focus of infection (Table 2). Pseudomonas
aeruginosa was the most common isolate overall (34.4%). Besides
Staphylococcus aureus (N= 28), Escherichia coli (N= 47) and Klebsiella
pneumoniae (N= 37) were also commonly found.
The vast majority of patients in both groups received 16 g of
piperacillin plus 2 g of tazobactam per day (80.9% of the
intermittent dosing group and 79.2% of the continuous infusion
group). The mean daily doses of piperacillin were 14.9 g and
14.8 g, respectively (p = 0.84). A second antibiotic, effective against
the isolated microorganism, was given to 31.2% of patients, 29.5%
of those receiving intermittent dosing and 32.9% continuous
infusion (p = 0.77).
A total of 98 patients (28.3%) died in the first 28 days after
starting piperacillin/tazobactam. No differences were found
related to the piperacillin/tazobactam mode of administration,
with 49 deaths in each group (p = 1.0). Mortality in the ICU was
also similar (continuous infusion 23.7% and intermittent dosing
20.2%, p= 0.512) as well as in-hospital mortality, 41.6% and
40.5% respectively (p = 0.913) – Table 3. Cumulative mortality in
the first 28 days after starting piperacillin/tazobactam is shown in
Figure 1. No significant differences in 28-day mortality were also
noted in any of the studied sub-groups (Table 4).
Stratifying patients according to SAPS II score allowed us to
identify the sub-group of patients with the largest 28-day mortality
difference. Patients with a SAPS II score above 42, had a 28-day
mortality rate of 35.2% when receiving piperacillin/tazobactam
by intermittent dosing and 31.4% if receiving continuous infusion,
but again this difference was not statistically significant (p = 0.66).
Among the patients discharged from the ICU, the median
length of ICU stay was similar for both groups (12.0 and 11.5 days,
respectively). In-hospital duration of stay was also not different
(Table 3).
Discussion
In this study we addressed the use of piperacillin/tazobactam
for the treatment of microbiologically documented infections
caused by susceptible species in critically ill patients. In this cohort
of patients, mostly treated with 16g/day of piperacillin plus 2g/
day of tazobactam, we found continuous infusion to be as effective
as conventional intermittent dosing, even in the most severe
patient sub-group.
Table 1. Demographic data from the selected matched cohort.
Intermittent Dosing (n =173) Continuous Infusion (n=173) P Value
Male Sex 114 (65.9%) 114 (65.9%) 1.0*
Age (years) 60.7618.2 60.8618.9 0.94**
Local of admission 0.803*
Emergency room 106 (61.3%) 107 (61.8%)
Ward 64 (37%) 62 (35.8%)
Another ICU 3 (1.7%) 4 (2.3%)
SAPS II 47.7614.7 47.5614.8 0.909**
Time in the ICU before piperacillin/tazobactam 0.845*
,72 hrs 96 (55.5%) 94 (54.3%)
3–7 days 42 (24.3%) 38 (22%)
8–28 days 30 (17.3%) 35 (20.2%)
.28 days 5 (2.9%) 6 (3.5%)
Systemic steroids 80 (46.2%) 87 (50.3%) 0.5*
Vasopressors 97 (56.1%) 96 (55.5%) 1.0*
Invasive mechanical ventilation 162 (93.6%) 159 (91.3%) 0.557*
Infection source 0.739*
Lung 125 (72.3%) 120 (69.4%)
Intra-abdominal 22 (12.7%) 21 (12.1%)
Genito-Urinary 14 (8.1%) 16 (9.2%)
Skin and Soft tissue 4 (2.3%) 4 (2.3%)
Blood stream infections 8 (4.6%) 12 (6.9%)
Isolated bacteria 0.387*
NFGNB 79 (45.7%) 78 (45.1%)
Other Gram negative 64 (37%) 62 (35.8%)
Gram positive 30 (17.3%) 33 (19.1%)
SAPS II - Simplified Acute Physiology Score; ICU – Intensive Care Unit; NFGNB – Non-fermenting Gram-negative bacteria.
Data presented as mean 6 standard deviation or N (percentage).
*McNemar’s test;
**Paired Student’s t test.
doi:10.1371/journal.pone.0049845.t001
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The b-lactam antibiotics, including piperacillin/tazobactam,
due to their large antimicrobial spectrum and low toxicity, are
among the first line therapy in critically ill septic patients. There is
large evidence that its pharmacodynamic target, associated with
the maximal microbiological effect, is the time during which the
non-protein bound drug concentration exceeds the MIC of the
organism (fT.MIC) [11]. Therefore extended or even continuous
infusion of b-lactam antibiotics has gained enthusiasm, since an
improved profile of b-lactams and a longer bacterial exposure can
be expected [15,16]. Several studies reported small benefits of
continuous infusion which has further been supported by
pharmacodynamic modelling studies [9].
Continuous infusion has also been shown to increase piper-
acillin/tazobactam lung epithelial lining fluid concentration [17]
but only in patients with normal renal function. No differences
were found in patients with moderate renal failure (creatinine
clearance,50 mL/min) and no survival benefit has been reported
[17].
In a retrospective cohort study of patients with ventilator-
associated pneumonia, Lorente et al [18] identified a higher
survival rate in patients receiving continuous infusion (90.5%)
compared with conventional intermittent dosing, 59.6%. Reduced
mortality with extended infusion piperacillin/tazobactam (4-hour
infusion) was also described in a single-center cohort study of 194
seriously ill patients with Pseudomonas aeruginosa infection [14].
However, in this study, only in the subset of the more severe
patients (according to an Acute Physiology and Chronic Health
Evaluation II score [19] higher than 17) a lower 14-day mortality
rate was associated with extended infusion (12.2% vs. 31.6%;
p= 0.04).
In contrast to our study, both these studies were single centre,
addressing only a specific population, ventilator associated
pneumonia [18] and Pseudomonas aeruginosa infection [14]. More-
over patients were not matched according to clinical variables and
unknown bias may have been introduced.
Pharmacodynamic modelling had also suggested a potential
benefit of extended or continuous infusion of b-lactams antibiotics
in outcome, but this was especially noted for bacteria with a high
MIC, near the antibiotic susceptibility breakpoint [20,21].
Although we did not evaluate the MICs of all isolated bacteria,
we exclude patients with resistant or intermediate isolated
microorganisms.
A recently published randomized control single center trial
compared another b-lactam, meropenem, either in continuous
infusion or in intermittent dosing, in 240 ICU young patients
(mean age 46 years), mostly with hospital acquired infections [7].
There was no survival benefit in the overall population (83.0% in
the continuous infusion group and 75.0% in the intermittent
dosing group; p= 0.18) or in the sub-group with the higher
APACHE II score (75.5% vs. 79.2%; p= 0.81). Although patients
in the intermittent dosing group received a high meropenem dose
(6g/day), those who receive continuous infusion had a higher rate
of microbiological success [Odds Ratio - 2.98 (95% confidence
interval 1.05 to 8.44; p = 0.04] and a lower length of stay in the
ICU, despite receiving a lower total dose of meropenem.
Two recently published meta-analysis of randomized, prospec-
tive studies also failed to show any survival benefit of the mode of
b-lactam antibiotics administration, extended or continuous
infusion [9,10] with odds ratio of 1.0 and 0.92, respectively.
To identify any subset of patients who had a significant
mortality benefit of continuous infusion in our study, we stratify
our population according to their severity scores, as was described
in the study of Lodise et al [14]. Accordingly we found that the
largest mortality difference was in the subset of patients with a
SAPS II.42. Using that cut-off, a non significant lower mortality
rate (31.4% vs. 35.2%) in patients receiving continuous infusion
was noted. To adequately confirm this difference (with a power of
80%), a study including 4822 patients would have been needed.
The clinical benefits of continuous infusion of piperacillin/
tazobactam may be mostly noted in patients infected with bacteria
with high MIC, in whom conventional intermittent dosing may
fail to achieve the pharmacodynamic target (fT.MIC), in
immunocompromissed patients [22] and in patients with increased
b-lactam clearance (closely related to creatinine clearance), who
may also be at risk of underdosing and, consequently, therapeutic
failure [23,24,25]. However the use of high b-lactam antibiotics
dose (as in the study of Chytra et al [7]) may overcome any
potential limitations of intermittent dosing. This could have also
contributed to our findings.
An increase in creatinine clearance, which is usually related to a
shorter fT.MIC of b-lactam antibiotics, has been shown to be a
common finding in septic surgical or trauma patients [26] and also







Enterobacter cloacae 10 4
Escherichia coli 14 9
Haemophilus influenzae 8 10
Klebsiella pneumoniae 14 9
Pseudomonas aeruginosa 45 45
Other NFGNB 3 4
Other Gram-negative 10 17
Gram-positive 21 22
Staphylococcus aureus 11 14
Streptococcus pneumoniae 5 7
Other Gram-positive 5 1
Abdomen
Gram-negative 20 20
Escherichia coli 2 6
Klebsiella pneumoniae 4 5
Pseudomonas aeruginosa 12 7




Escherichia coli 4 12
Klebsiella pneumoniae 3 2
Pseudomonas aeruginosa 4 6
Other Gram-negative 7 3
Gram-Positive 8 9
Enterococcus faecalis 2 3
Staphylococcus aureus 4 5
Other Gram-positive 2 1
All included microorganisms had in vitro susceptibility to piperacillin/
tazobactam.
NFGNB – Non-fermenting Gram-negative bacteria.
doi:10.1371/journal.pone.0049845.t002
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in medical patients [27]. An effort to identify easily available
clinical markers of patients at risk for underdosing, who might
benefit from an improved pharmacokinetic dosing guidance
(including continuous infusion of b-lactam antibiotics) is currently
underway [28,29].
A large volume of distribution is also common in critically ill
septic patients. Therefore failure to give an appropriate loading
dose may also lead to an initially low fT.MIC [30]. However, due
to the fact that volume of distribution and half-life are directly
proportional, the enhanced volume of distribution can increase
drug half-life (and consequently fT.MIC) [31], as long as drug
clearance remains unchanged.
Critically ill patients with organ dysfunction commonly
experience drug accumulation and toxicity [32] and this may
easily go unrecognized [33,34]. Consequently therapeutic drug
monitoring has been proposed as a valuable tool to help guide
antibiotic therapy, unveiling both under and overdosing [35,36].
Presently this is only commonly available for aminoglycosides and
vancomycin. Furthermore, better guidance of the ideal therapeutic
targets of b-lactam antibiotics are probably needed [37].
As far as we are aware, this is the largest study evaluating the
outcomes of patients treated with continuous infusion of a b-
lactam antibiotic, evaluating 346 patients. Moreover it is a
multicenter study which included critically ill patients with
different microbiologically documented infections caused by
bacteria susceptible to the study drug, matched by a propensity
based analysis. We believe that this data suggests that the use of
continuous infusion of 16g/day of piperacillin plus 2g/day of
tazobactam in a heterogeneous group of critically ill patients is not
associated with a decrease in mortality. Studies to identify sub-
groups of critically ill patients who could benefit from this strategy
are warranted.
However our study has also some limitations. First we did not
measure piperacillin/tazobactam concentrations. Also, data on
bacteria MIC was not available for analysis. Therefore we were
not able to identify patients who did not attain the piperacillin/
tazobactam pharmacodynamic target or who had toxic concen-
trations. We also cannot exclude an eventual difference of efficacy
of continuous infusion of piperacillin/tazobactam in patients
infected with borderline resistant bacteria, as we only included
Figure 1. Cumulative mortality in the first 28 days after starting piperacillin/tazobactam therapy either in continuous infusion
(dashed line) or 30 min bolus dosing (solid line).
doi:10.1371/journal.pone.0049845.g001
Table 3. Outcomes of patients treated with piperacillin/tazobactam, either as continuous infusion or intermittent dosing.
Continuous Infusion (n =173) Intermittent dosing (n=173) P value
28-day mortality 28.3% 28.3% 1.0*
ICU mortality 23.7% 20.2% 0.512*
In-Hospital mortality 41.6% 40.5% 0.913**
Length of ICU stay1 12 [14] 11.5 [11] 0.582**
Length of Hospital stay2 30 [32] 31 [54] 0.475**
SAPS II.42 (N, 28 day mortality) 105, 31.4% 108, 35.2% 0.66#
1Patients discharged from ICU;
2Patients discharged from hospital.
ICU – Intensive Care Unit; SAPS - Simplified Acute Physiology Score.
Data presented as percentage or median [Interquartile Range].
*McNemar’s test;
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patients with susceptible bacteria. Second this was a retrospective
study, addressing a heterogeneous ICU population and, despite
the matching, some unknown bias may have occurred. Besides, we
recognize that our sample may have been underpowered to unveil
differences in some sub-groups of interest. Finally we did not
analyse data on antibiotic duration or recurrent infection, as
several patients were discharged from the ICU while still receiving
the antibiotic.
Conclusions
In this cohort of heterogeneous critically ill patients with
infections caused by susceptible bacteria, the clinical efficacy of
16g/day of piperacillin plus 2g/day of tazobactam was indepen-
dent of the mode of administration, either continuous infusion or
conventional intermittent dosing.
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